Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial

被引:32
作者
Buelens, Sarah [1 ,2 ]
Poelaert, Filip [1 ,2 ]
Dhondt, Bert [1 ,2 ]
Fonteyne, Valerie [3 ]
De Visschere, Pieter [4 ]
Ost, Piet [2 ,3 ]
Verbeke, Sofie [3 ]
Villeirs, Geert [4 ]
De Man, Kathia [5 ]
Rottey, Sylvie [6 ]
Decaestecker, Karel [1 ]
Lumen, Nicolaas [1 ,2 ]
机构
[1] Ghent Univ Hosp, Dept Urol, Ghent, Belgium
[2] Univ Ghent, Canc Res Inst Ghent, Dept Radiat Oncol & Expt Canc Res, Ghent, Belgium
[3] Ghent Univ Hosp, Dept Pathol, Ghent, Belgium
[4] Ghent Univ Hosp, Dept Radiol, Ghent, Belgium
[5] Ghent Univ Hosp, Dept Nucl Med, Ghent, Belgium
[6] Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium
关键词
Prostate cancer; Metastatic load; Hormone sensitive; CHAARTED; LATITUDE; Outcome; ESTRO-SIOG GUIDELINES; RADICAL PROSTATECTOMY; PROGNOSTIC-FACTORS; CASTRATION; SURVIVAL; DOCETAXEL; CARCINOMA; AGREEMENT; THERAPY; SITE;
D O I
10.1016/j.urolonc.2017.12.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: No uniformity exists in the definition of metastatic burden in metastatic hormone-naive prostate cancer (mHNPC) across clinical trials making their comparison challenging. We explored definition agreement and prognostic significance of bulky mHNPC according to the CHAARTED and LATITUDE trial. Materials and methods: Since 2014, 95 patients with newly diagnosed mHNPC were prospectively registered. For this study, they were categorized as having high-volume (HVD) vs. low-volume (LVD) and high-risk (HRD) vs. low-risk disease (LRD) according to the definition of CHAARTED and LATITUDE, respectively. Agreement was tested using Cohen's K coefficient. The Kaplan-Meier method was used to compare castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). Prognostic significance was analyzed using Cox regression models. Results: In total, 44 (46%) and 46 (48%) patients showed HVD and HRD, respectively. Cohen's K coefficient was 0.83 indicating "almost perfect" agreement (P < 0.001). Median CRPC-FS was 40 (95% CI: 25-55) vs. 11 months (95% CI: 8-14) for LVD and HVD (P = 0.001); 40 (95% CI: 27-53) vs. 11 months (95% CI: 8-14) for LRD and HRD (P < 0.001), respectively. Median OS was not reached vs. 51 months (95% CI: 0-102) for LVD and HVD (P = 0.001); not reached vs. 51 months (95% CI: 2-100) for LRD and HRD (P = 0.003), respectively. The prognostic significance of both definitions remained significant in the multivariate model for CRPC-FS (P = 0.012 and P = 0.003). Conclusions: There is an excellent agreement between the definitions of bulky mHNPC in the CHAARTED and LATITUDE trial. Both definitions have significant prognostic value for predicting worse CRPC-FS and OS. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:158.e13 / 158.e20
页数:8
相关论文
共 50 条
[21]   Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials [J].
Robert J. van Soest ;
Ronald de Wit .
BMC Medicine, 13
[22]   Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial [J].
Fabien Calcagno ;
Guillaume Mouillet ;
Olivier Adotevi ;
Tristan Maurina ;
Thierry Nguyen ;
Philippe Montcuquet ;
E. Curtit ;
F. Kleinclauss ;
Xavier Pivot ;
Christophe Borg ;
Antoine Thiery-Vuillemin .
Medical Oncology, 2016, 33
[23]   New developments in the management of newly diagnosed metastatic prostate cancer [J].
Leone, Gianmarco ;
Alifrangis, Constantine .
TRENDS IN UROLOGY & MENS HEALTH, 2023, 14 (03) :6-9
[24]   Local Radiotherapy for Patients with newly diagnosed, metastatic Prostate Cancer [J].
Guckenberger, Matthias .
STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (04) :362-364
[25]   Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed? [J].
Damodaran, Shivashankar ;
Kyriakopoulos, Christos E. ;
Jarrard, David F. .
UROLOGIC CLINICS OF NORTH AMERICA, 2017, 44 (04) :611-+
[26]   Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review [J].
Ong, Sean ;
O'Brien, Jonathan ;
Medhurst, Elizabeth ;
Lawrentschuk, Nathan ;
Murphy, Declan ;
Azad, Arun .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (10) :3918-3930
[27]   Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial [J].
Martini, Alberto ;
Pfail, John ;
Montorsi, Francesco ;
Galsky, Matthew D. ;
Oh, William K. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (04) :638-645
[28]   External validation of the prostascore model in patients with metastatic hormone-sensitive prostate cancer recruited to the CHAARTED study [J].
Abdel-Rahman, Omar ;
Cheung, Winson Y. .
BJU INTERNATIONAL, 2018, 122 (03) :394-400
[29]   Efficacy and Adverse Events of Docetaxel for Metastatic, Hormone-sensitive Prostate Cancer Among Elderly Men: A Post Hoc Analysis of the CHAARTED Trial [J].
Li, Eric, V ;
Siddiqui, Mohammad R. ;
Weiner, Adam B. ;
Prizment, Anna E. ;
Ryan, Charles J. ;
Morgans, Alicia K. .
CLINICAL GENITOURINARY CANCER, 2021, 19 (05) :388-395
[30]   Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer [J].
Sarah Buelens ;
Elise De Bleser ;
Bert Dhondt ;
Wesley Verla ;
Karel Decaestecker ;
Piet Ost ;
Valérie Fonteyne ;
Kathia De Man ;
Chloë Standaert ;
Sylvie Rottey ;
Nicolaas Lumen .
World Journal of Urology, 2019, 37 :2565-2571